38 completed. 38 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Completed 38 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow Candidiasis: new trials by email Literature Review of Candidiasis trials Research Report on Candidiasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia Interferon Gamma-1B - Candidemia | Phase 2 | Completed | Radboud University Medical Center | 65 | 2022-03-31 | 2026-06-22 |
| An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris APX001 - Candidemia, Invasive Candidiases | Phase 2 | Completed | Basilea Pharmaceutica | 9 | 2019-12-13 | 2025-09-16 |
| An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia APX001 - Candidemia | Phase 2 | Completed | Basilea Pharmaceutica | 21 | 2018-10-03 | 2025-09-16 |
| Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Fluconazole, SCY-078 - Candida Vulvovaginitis | Phase 2 | Completed | Scynexis, Inc. | 186 | 2017-08-01 | 2021-08-12 |
| ProF-001_Phase IIa Candiplus, Clotrimazole - Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Completed | ProFem GmbH | 84 | 2017-04-04 | 2019-03-14 |
| Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Oral Encochleated Amphotericin B (CAMB), Fluconazole - Vulvovaginitis, Yeast Infection | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 137 | 2016-11-01 | 2018-11-02 |
| CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Amphotericin B - Candidiasis, Chronic Mucocutaneous | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 4 | 2016-09-27 | 2024-08-07 |
| CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension CD101, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 207 | 2016-07-26 | 2020-12-08 |
| TOL-463 Phase 2 Study for Vaginitis TOL-463 - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 2 | Completed | Toltec Pharmaceuticals, LLC | 106 | 2016-07-15 | 2018-03-09 |
| RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%) - Candidiasis, Vulvovaginal, Mycoses | Phase 2 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 126 | 2016-06-08 | 2020-08-31 |
| Efficacy of 1% Nanochitosan Solution in the Treatment of Denture Stomatitis 1% Nanochitosan Solution, Nystatin Oral Suspension - Denture Stomatitis, Chronic Atrophic Candidiasis | Phase 2 | Completed | Kerman University of Medical Sciences | 30 | 2016-01-17 | 2026-07-13 |
| Efficacy of 5% Nanochitosan Paste in the Treatment of Oral Candidosis 5% Nanochitosan Paste, Nystatin Ointment - Denture Stomatitis, Oral Candidosis | Phase 2 | Completed | Kerman University of Medical Sciences | 30 | 2016-01-01 | 2026-09-10 |
| Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis SCY-078, Fluconazole - Vulvovaginal Candidiasis | Phase 2 | Completed | Scynexis, Inc. | 96 | 2015-11-01 | 2019-07-12 |
| Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis Micafungin - Candidiasis, Systemic, Candida Meningitis | Phase 2 | Completed | Astellas Pharma Global Development, Inc. | 35 | 2015-05-30 | 2024-11-18 |
| A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) VT-1161, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 2 | Completed | Viamet | 254 | 2015-02-10 | 2019-10-15 |
| Probiotic Implementation as Help in Solving Vaginal Infections Lactobacillus rhamnosus BMX 54 - Vaginal Infection, ASC-US | Phase 2 | Completed | University of Roma La Sapienza | 117 | 2015-02-01 | 2017-12-13 |
| Fluconazole Versus Micafungin in Neonates With Candidiasis Fluconazole, Micafungin - Candidiasis | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 100 | 2014-10-01 | 2025-09-04 |
| Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis SCY-078, Fluconazole, Micafungin - Mycoses, Candidiasis, Invasive | Phase 2 | Completed | Scynexis, Inc. | 27 | 2014-09-01 | 2024-06-25 |
| A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection) VT-1161, Fluconazole - Candidiasis, Vulvovaginal | Phase 2 | Completed | Viamet | 55 | 2013-08-01 | 2018-08-01 |
Showing 20 of 38. Sign in to see all of them.
Candidiasis, Vulvovaginal (14) · Candidemia (8) · Candidiasis, Invasive (6) · Candidiasis, Oral (5) · Mycoses (4) · Aspergillosis (3) · Stomatitis, Denture (3) · HIV Infections (2) · Torulopsis (2) · Vaginitis (2) · Vaginosis, Bacterial (2) · AIDS-Related Complex (1) · AIDS-Related Opportunistic Infections (1) · Acquired Immunodeficiency Syndrome (1)
Bacterial Infections and Mycoses (38) · Infections (38) · Mycoses (34) · Genital Diseases (16) · Urogenital Diseases (16) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Genital Diseases, Female (14) · Vulvar Diseases (14) · Vulvitis (14) · Vaginal Diseases (13) · Vulvovaginitis (13) · Vaginitis (12) · Invasive Fungal Infections (10)
Fluconazole (9) · Caspofungin (5) · Micafungin (4) · ibrexafungerp (3) · Amphotericin B (2) · Anidulafungin (2) · VT-1161 (2) · Antifungal Agents (1) · Clotrimazole (1) · Injections (1) · Miconazole (1) · TOL-463 (1) · Voriconazole (1) · interferon gamma-1b (1) · octenidine (1)
Merck Sharp & Dohme LLC (5) · Pfizer (3) · Scynexis, Inc. (3) · Basilea Pharmaceutica (2) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Kerman University of Medical Sciences (2) · Matinas BioPharma Nanotechnologies, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Viamet (2) · Almirall, S.A. (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1) · Ferrer Internacional S.A. (1) · Hadassah Medical Organization (1) · Institut National de la Santé Et de la Recherche Médicale, France (1)
United States (20) · Germany (6) · Spain (6) · Belgium (4) · Italy (4) · France (3) · Israel (3) · Austria (2) · Canada (2) · Dominican Republic (2) · Greece (2) · Guatemala (2) · Honduras (2) · Netherlands (2) · Romania (2)
David Angulo, MD (3) · Marc Engelhardt (2) · Alena Jandourek, MD (1) · Alexandra Freeman, MD (1) · Christoph Willers, MD, MBA (1) · Douglas Kling (1) · Gregory Reid, MSc, MBA (1) · Herbert Kiss, Ao.Univ.Prof.Dr. (1) · John P. Hennessey, Jr., Ph.D. (1) · Rakefet Czerninski, DMD (1) · Sumita Bhatia, MD (1)
PMID 36396498, PMID 16436724, PMID 25701307, PMID 29304768, PMID 29534874, PMID 29697768, PMID 29744900, PMID 30184181, PMID 32818963, PMID 32955088, PMID 33558294, PMID 34555149, PMID 35699443, PMID 37022196, PMID 37596890, PMID 38008099, PMID 38502709, PMID 39468640, PMID 39529079, PMID 40970688, PMID 41940006
2009 (2), 2014 (1), 2015 (1)